Skip to main content

Table 2 Uni- and multivariate Cox regression analysis

From: Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the ‘TOaSTT’ database

Variables OS PFS TTS
Univariate Multivariate Univariate Multivariate Univariate Multivariate
p value p value HR (95% CI) p value p value HR (95% CI) p value p value HR (95% CI)
Cinical metastatic status (OPD, palliative intent) 0.006 0.002 2.03 (1.30–3.17) 0.002 0.334   0.053 0.938 1.0 (0.56–1.81)
Initial stage (I–IV) 0.567 0.402    0.561   
Metastatic development (synchronous vs. metachronous) 0.802 0.895    0.653   
Previous lines of systemic treatment (1 vs. > 1) 0.166 0.109 0.048 0.033 1.7 (1.05–2.77) 0.093 0.152 1.57 (0.84–2.92)
Metastatic burden (1, 2–5, 6–10, > 10) 0.461 0.062 0.759   0.051 0.686 1.10 (0.741.64)
Affected organs (1 vs. > 1) 0.03 0.633 0.004 0.023 2.04 (1.10–3.79) 0.026 0.031 2.53 (1.09–5.89)
Location of metastases (cranial vs. extracranial) 0.201 0.827 0.155 0.757   0.48   
Histology subtype (SqCC, ADC, LCNEC, adenosquamous, unknown) 0.952 0.554    0.447   
Gene mutation (yes vs. no) 0.834 0.992    0.696   
Status of primary tumor (controlled vs. progressive) 0.973 0.701    0.824   
Targeted therapy (IT, TT, AAT) 0.855 0.424    0.64   
SRT location (cranial, extracranial, both) 0.25 0.149 0.571   0.767   
Number of SRT treated metastases (1–5) 0.642 0.993    0.509   
Start targeted therapy (before, during, after SRT) 0.239 0.436    0.299   
Targeted therapy paused during SRT (yes vs no) 0.645 0.734    0.104 0.393 1.32 (0.75–2.34)
  1. p < 0.05 is significant
  2. HR  hazard ratio, CI confidence interval, TT targeted therapy, IT immunotherapy, AAT antiangiogenic therapy, PARPi  PARP-inhibitor